Table of Content

1 Metastatic Melanoma Drug Market Overview
1.1 Product Overview and Scope of Metastatic Melanoma Drug
1.2 Metastatic Melanoma Drug Segment by Type
1.2.1 Global Metastatic Melanoma Drug Market Value Comparison by Type (2024-2034)
1.2.2 AGI-134
1.2.3 ALT-801
1.2.4 ALT-803
1.2.5 AMG-232
1.2.6 Others
1.3 Metastatic Melanoma Drug Segment by Application
1.3.1 Global Metastatic Melanoma Drug Market Value by Application: (2024-2034)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Metastatic Melanoma Drug Market Size Estimates and Forecasts
1.4.1 Global Metastatic Melanoma Drug Revenue 2018-2034
1.4.2 Global Metastatic Melanoma Drug Sales 2018-2034
1.4.3 Global Metastatic Melanoma Drug Market Average Price (2018-2034)
1.5 Assumptions and Limitations
2 Metastatic Melanoma Drug Market Competition by Manufacturers
2.1 Global Metastatic Melanoma Drug Sales Market Share by Manufacturers (2018-2024)
2.2 Global Metastatic Melanoma Drug Revenue Market Share by Manufacturers (2018-2024)
2.3 Global Metastatic Melanoma Drug Average Price by Manufacturers (2018-2024)
2.4 Global Metastatic Melanoma Drug Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Metastatic Melanoma Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Metastatic Melanoma Drug, Product Type & Application
2.7 Metastatic Melanoma Drug Market Competitive Situation and Trends
2.7.1 Metastatic Melanoma Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Metastatic Melanoma Drug Players Market Share by Revenue
2.7.3 Global Metastatic Melanoma Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Metastatic Melanoma Drug Retrospective Market Scenario by Region
3.1 Global Metastatic Melanoma Drug Market Size by Region: 2018 Versus 2022 Versus 2034
3.2 Global Metastatic Melanoma Drug Global Metastatic Melanoma Drug Sales by Region: 2018-2034
3.2.1 Global Metastatic Melanoma Drug Sales by Region: 2018-2024
3.2.2 Global Metastatic Melanoma Drug Sales by Region: 2024-2034
3.3 Global Metastatic Melanoma Drug Global Metastatic Melanoma Drug Revenue by Region: 2018-2034
3.3.1 Global Metastatic Melanoma Drug Revenue by Region: 2018-2024
3.3.2 Global Metastatic Melanoma Drug Revenue by Region: 2024-2034
3.4 North America Metastatic Melanoma Drug Market Facts & Figures by Country
3.4.1 North America Metastatic Melanoma Drug Market Size by Country: 2018 VS 2022 VS 2034
3.4.2 North America Metastatic Melanoma Drug Sales by Country (2018-2034)
3.4.3 North America Metastatic Melanoma Drug Revenue by Country (2018-2034)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Metastatic Melanoma Drug Market Facts & Figures by Country
3.5.1 Europe Metastatic Melanoma Drug Market Size by Country: 2018 VS 2022 VS 2034
3.5.2 Europe Metastatic Melanoma Drug Sales by Country (2018-2034)
3.5.3 Europe Metastatic Melanoma Drug Revenue by Country (2018-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Metastatic Melanoma Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Metastatic Melanoma Drug Market Size by Country: 2018 VS 2022 VS 2034
3.6.2 Asia Pacific Metastatic Melanoma Drug Sales by Country (2018-2034)
3.6.3 Asia Pacific Metastatic Melanoma Drug Revenue by Country (2018-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Metastatic Melanoma Drug Market Facts & Figures by Country
3.7.1 Latin America Metastatic Melanoma Drug Market Size by Country: 2018 VS 2022 VS 2034
3.7.2 Latin America Metastatic Melanoma Drug Sales by Country (2018-2034)
3.7.3 Latin America Metastatic Melanoma Drug Revenue by Country (2018-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Metastatic Melanoma Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Metastatic Melanoma Drug Market Size by Country: 2018 VS 2022 VS 2034
3.8.2 Middle East and Africa Metastatic Melanoma Drug Sales by Country (2018-2034)
3.8.3 Middle East and Africa Metastatic Melanoma Drug Revenue by Country (2018-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Metastatic Melanoma Drug Sales by Type (2018-2034)
4.1.1 Global Metastatic Melanoma Drug Sales by Type (2018-2024)
4.1.2 Global Metastatic Melanoma Drug Sales by Type (2024-2034)
4.1.3 Global Metastatic Melanoma Drug Sales Market Share by Type (2018-2034)
4.2 Global Metastatic Melanoma Drug Revenue by Type (2018-2034)
4.2.1 Global Metastatic Melanoma Drug Revenue by Type (2018-2024)
4.2.2 Global Metastatic Melanoma Drug Revenue by Type (2024-2034)
4.2.3 Global Metastatic Melanoma Drug Revenue Market Share by Type (2018-2034)
4.3 Global Metastatic Melanoma Drug Price by Type (2018-2034)
5 Segment by Application
5.1 Global Metastatic Melanoma Drug Sales by Application (2018-2034)
5.1.1 Global Metastatic Melanoma Drug Sales by Application (2018-2024)
5.1.2 Global Metastatic Melanoma Drug Sales by Application (2024-2034)
5.1.3 Global Metastatic Melanoma Drug Sales Market Share by Application (2018-2034)
5.2 Global Metastatic Melanoma Drug Revenue by Application (2018-2034)
5.2.1 Global Metastatic Melanoma Drug Revenue by Application (2018-2024)
5.2.2 Global Metastatic Melanoma Drug Revenue by Application (2024-2034)
5.2.3 Global Metastatic Melanoma Drug Revenue Market Share by Application (2018-2034)
5.3 Global Metastatic Melanoma Drug Price by Application (2018-2034)
6 Key Companies Profiled
6.1 Merck & Co., Inc.
6.1.1 Merck & Co., Inc. Corporation Information
6.1.2 Merck & Co., Inc. Description and Business Overview
6.1.3 Merck & Co., Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2018-2024)
6.1.4 Merck & Co., Inc. Metastatic Melanoma Drug Product Portfolio
6.1.5 Merck & Co., Inc. Recent Developments/Updates
6.2 Merck KGaA
6.2.1 Merck KGaA Corporation Information
6.2.2 Merck KGaA Description and Business Overview
6.2.3 Merck KGaA Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2018-2024)
6.2.4 Merck KGaA Metastatic Melanoma Drug Product Portfolio
6.2.5 Merck KGaA Recent Developments/Updates
6.3 Millennium Pharmaceuticals, Inc.
6.3.1 Millennium Pharmaceuticals, Inc. Corporation Information
6.3.2 Millennium Pharmaceuticals, Inc. Description and Business Overview
6.3.3 Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2018-2024)
6.3.4 Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Product Portfolio
6.3.5 Millennium Pharmaceuticals, Inc. Recent Developments/Updates
6.4 Morphotek, Inc.
6.4.1 Morphotek, Inc. Corporation Information
6.4.2 Morphotek, Inc. Description and Business Overview
6.4.3 Morphotek, Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Morphotek, Inc. Metastatic Melanoma Drug Product Portfolio
6.4.5 Morphotek, Inc. Recent Developments/Updates
6.5 NewLink Genetics Corporation
6.5.1 NewLink Genetics Corporation Corporation Information
6.5.2 NewLink Genetics Corporation Description and Business Overview
6.5.3 NewLink Genetics Corporation Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2018-2024)
6.5.4 NewLink Genetics Corporation Metastatic Melanoma Drug Product Portfolio
6.5.5 NewLink Genetics Corporation Recent Developments/Updates
6.6 Novartis AG
6.6.1 Novartis AG Corporation Information
6.6.2 Novartis AG Description and Business Overview
6.6.3 Novartis AG Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2018-2024)
6.6.4 Novartis AG Metastatic Melanoma Drug Product Portfolio
6.6.5 Novartis AG Recent Developments/Updates
6.7 Omeros Corporation
6.6.1 Omeros Corporation Corporation Information
6.6.2 Omeros Corporation Description and Business Overview
6.6.3 Omeros Corporation Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Omeros Corporation Metastatic Melanoma Drug Product Portfolio
6.7.5 Omeros Corporation Recent Developments/Updates
6.8 Oncolytics Biotech Inc.
6.8.1 Oncolytics Biotech Inc. Corporation Information
6.8.2 Oncolytics Biotech Inc. Description and Business Overview
6.8.3 Oncolytics Biotech Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2018-2024)
6.8.4 Oncolytics Biotech Inc. Metastatic Melanoma Drug Product Portfolio
6.8.5 Oncolytics Biotech Inc. Recent Developments/Updates
6.9 OncoSec Medical Inc.
6.9.1 OncoSec Medical Inc. Corporation Information
6.9.2 OncoSec Medical Inc. Description and Business Overview
6.9.3 OncoSec Medical Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2018-2024)
6.9.4 OncoSec Medical Inc. Metastatic Melanoma Drug Product Portfolio
6.9.5 OncoSec Medical Inc. Recent Developments/Updates
6.10 Ono Pharmaceutical Co., Ltd.
6.10.1 Ono Pharmaceutical Co., Ltd. Corporation Information
6.10.2 Ono Pharmaceutical Co., Ltd. Description and Business Overview
6.10.3 Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2018-2024)
6.10.4 Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Product Portfolio
6.10.5 Ono Pharmaceutical Co., Ltd. Recent Developments/Updates
6.11 Pfizer Inc.
6.11.1 Pfizer Inc. Corporation Information
6.11.2 Pfizer Inc. Metastatic Melanoma Drug Description and Business Overview
6.11.3 Pfizer Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2018-2024)
6.11.4 Pfizer Inc. Metastatic Melanoma Drug Product Portfolio
6.11.5 Pfizer Inc. Recent Developments/Updates
6.12 Pharmis Biofarmaceutica, Lda.
6.12.1 Pharmis Biofarmaceutica, Lda. Corporation Information
6.12.2 Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Description and Business Overview
6.12.3 Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2018-2024)
6.12.4 Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Product Portfolio
6.12.5 Pharmis Biofarmaceutica, Lda. Recent Developments/Updates
6.13 Philogen S.p.A.
6.13.1 Philogen S.p.A. Corporation Information
6.13.2 Philogen S.p.A. Metastatic Melanoma Drug Description and Business Overview
6.13.3 Philogen S.p.A. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2018-2024)
6.13.4 Philogen S.p.A. Metastatic Melanoma Drug Product Portfolio
6.13.5 Philogen S.p.A. Recent Developments/Updates
6.14 Plexxikon Inc.
6.14.1 Plexxikon Inc. Corporation Information
6.14.2 Plexxikon Inc. Metastatic Melanoma Drug Description and Business Overview
6.14.3 Plexxikon Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2018-2024)
6.14.4 Plexxikon Inc. Metastatic Melanoma Drug Product Portfolio
6.14.5 Plexxikon Inc. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Metastatic Melanoma Drug Industry Chain Analysis
7.2 Metastatic Melanoma Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Metastatic Melanoma Drug Production Mode & Process
7.4 Metastatic Melanoma Drug Sales and Marketing
7.4.1 Metastatic Melanoma Drug Sales Channels
7.4.2 Metastatic Melanoma Drug Distributors
7.5 Metastatic Melanoma Drug Customers
8 Metastatic Melanoma Drug Market Dynamics
8.1 Metastatic Melanoma Drug Industry Trends
8.2 Metastatic Melanoma Drug Market Drivers
8.3 Metastatic Melanoma Drug Market Challenges
8.4 Metastatic Melanoma Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Metastatic Melanoma Drug Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Metastatic Melanoma Drug Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Metastatic Melanoma Drug Market Competitive Situation by Manufacturers in 2022
Table 4. Global Metastatic Melanoma Drug Sales (K Pcs) of Key Manufacturers (2018-2024)
Table 5. Global Metastatic Melanoma Drug Sales Market Share by Manufacturers (2018-2024)
Table 6. Global Metastatic Melanoma Drug Revenue (US$ Million) by Manufacturers (2018-2024)
Table 7. Global Metastatic Melanoma Drug Revenue Share by Manufacturers (2018-2024)
Table 8. Global Market Metastatic Melanoma Drug Average Price (USD/Pcs) of Key Manufacturers (2018-2024)
Table 9. Global Key Players of Metastatic Melanoma Drug, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Metastatic Melanoma Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Metastatic Melanoma Drug, Product Type & Application
Table 12. Global Key Manufacturers of Metastatic Melanoma Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Metastatic Melanoma Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metastatic Melanoma Drug as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Metastatic Melanoma Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2034
Table 17. Global Metastatic Melanoma Drug Sales by Region (2018-2024) & (K Pcs)
Table 18. Global Metastatic Melanoma Drug Sales Market Share by Region (2018-2024)
Table 19. Global Metastatic Melanoma Drug Sales by Region (2024-2034) & (K Pcs)
Table 20. Global Metastatic Melanoma Drug Sales Market Share by Region (2024-2034)
Table 21. Global Metastatic Melanoma Drug Revenue by Region (2018-2024) & (US$ Million)
Table 22. Global Metastatic Melanoma Drug Revenue Market Share by Region (2018-2024)
Table 23. Global Metastatic Melanoma Drug Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global Metastatic Melanoma Drug Revenue Market Share by Region (2024-2034)
Table 25. North America Metastatic Melanoma Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 26. North America Metastatic Melanoma Drug Sales by Country (2018-2024) & (K Pcs)
Table 27. North America Metastatic Melanoma Drug Sales by Country (2024-2034) & (K Pcs)
Table 28. North America Metastatic Melanoma Drug Revenue by Country (2018-2024) & (US$ Million)
Table 29. North America Metastatic Melanoma Drug Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe Metastatic Melanoma Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 31. Europe Metastatic Melanoma Drug Sales by Country (2018-2024) & (K Pcs)
Table 32. Europe Metastatic Melanoma Drug Sales by Country (2024-2034) & (K Pcs)
Table 33. Europe Metastatic Melanoma Drug Revenue by Country (2018-2024) & (US$ Million)
Table 34. Europe Metastatic Melanoma Drug Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific Metastatic Melanoma Drug Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 36. Asia Pacific Metastatic Melanoma Drug Sales by Region (2018-2024) & (K Pcs)
Table 37. Asia Pacific Metastatic Melanoma Drug Sales by Region (2024-2034) & (K Pcs)
Table 38. Asia Pacific Metastatic Melanoma Drug Revenue by Region (2018-2024) & (US$ Million)
Table 39. Asia Pacific Metastatic Melanoma Drug Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America Metastatic Melanoma Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 41. Latin America Metastatic Melanoma Drug Sales by Country (2018-2024) & (K Pcs)
Table 42. Latin America Metastatic Melanoma Drug Sales by Country (2024-2034) & (K Pcs)
Table 43. Latin America Metastatic Melanoma Drug Revenue by Country (2018-2024) & (US$ Million)
Table 44. Latin America Metastatic Melanoma Drug Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa Metastatic Melanoma Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 46. Middle East & Africa Metastatic Melanoma Drug Sales by Country (2018-2024) & (K Pcs)
Table 47. Middle East & Africa Metastatic Melanoma Drug Sales by Country (2024-2034) & (K Pcs)
Table 48. Middle East & Africa Metastatic Melanoma Drug Revenue by Country (2018-2024) & (US$ Million)
Table 49. Middle East & Africa Metastatic Melanoma Drug Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global Metastatic Melanoma Drug Sales (K Pcs) by Type (2018-2024)
Table 51. Global Metastatic Melanoma Drug Sales (K Pcs) by Type (2024-2034)
Table 52. Global Metastatic Melanoma Drug Sales Market Share by Type (2018-2024)
Table 53. Global Metastatic Melanoma Drug Sales Market Share by Type (2024-2034)
Table 54. Global Metastatic Melanoma Drug Revenue (US$ Million) by Type (2018-2024)
Table 55. Global Metastatic Melanoma Drug Revenue (US$ Million) by Type (2024-2034)
Table 56. Global Metastatic Melanoma Drug Revenue Market Share by Type (2018-2024)
Table 57. Global Metastatic Melanoma Drug Revenue Market Share by Type (2024-2034)
Table 58. Global Metastatic Melanoma Drug Price (USD/Pcs) by Type (2018-2024)
Table 59. Global Metastatic Melanoma Drug Price (USD/Pcs) by Type (2024-2034)
Table 60. Global Metastatic Melanoma Drug Sales (K Pcs) by Application (2018-2024)
Table 61. Global Metastatic Melanoma Drug Sales (K Pcs) by Application (2024-2034)
Table 62. Global Metastatic Melanoma Drug Sales Market Share by Application (2018-2024)
Table 63. Global Metastatic Melanoma Drug Sales Market Share by Application (2024-2034)
Table 64. Global Metastatic Melanoma Drug Revenue (US$ Million) by Application (2018-2024)
Table 65. Global Metastatic Melanoma Drug Revenue (US$ Million) by Application (2024-2034)
Table 66. Global Metastatic Melanoma Drug Revenue Market Share by Application (2018-2024)
Table 67. Global Metastatic Melanoma Drug Revenue Market Share by Application (2024-2034)
Table 68. Global Metastatic Melanoma Drug Price (USD/Pcs) by Application (2018-2024)
Table 69. Global Metastatic Melanoma Drug Price (USD/Pcs) by Application (2024-2034)
Table 70. Merck & Co., Inc. Corporation Information
Table 71. Merck & Co., Inc. Description and Business Overview
Table 72. Merck & Co., Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 73. Merck & Co., Inc. Metastatic Melanoma Drug Product
Table 74. Merck & Co., Inc. Recent Developments/Updates
Table 75. Merck KGaA Corporation Information
Table 76. Merck KGaA Description and Business Overview
Table 77. Merck KGaA Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 78. Merck KGaA Metastatic Melanoma Drug Product
Table 79. Merck KGaA Recent Developments/Updates
Table 80. Millennium Pharmaceuticals, Inc. Corporation Information
Table 81. Millennium Pharmaceuticals, Inc. Description and Business Overview
Table 82. Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 83. Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Product
Table 84. Millennium Pharmaceuticals, Inc. Recent Developments/Updates
Table 85. Morphotek, Inc. Corporation Information
Table 86. Morphotek, Inc. Description and Business Overview
Table 87. Morphotek, Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 88. Morphotek, Inc. Metastatic Melanoma Drug Product
Table 89. Morphotek, Inc. Recent Developments/Updates
Table 90. NewLink Genetics Corporation Corporation Information
Table 91. NewLink Genetics Corporation Description and Business Overview
Table 92. NewLink Genetics Corporation Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 93. NewLink Genetics Corporation Metastatic Melanoma Drug Product
Table 94. NewLink Genetics Corporation Recent Developments/Updates
Table 95. Novartis AG Corporation Information
Table 96. Novartis AG Description and Business Overview
Table 97. Novartis AG Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 98. Novartis AG Metastatic Melanoma Drug Product
Table 99. Novartis AG Recent Developments/Updates
Table 100. Omeros Corporation Corporation Information
Table 101. Omeros Corporation Description and Business Overview
Table 102. Omeros Corporation Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 103. Omeros Corporation Metastatic Melanoma Drug Product
Table 104. Omeros Corporation Recent Developments/Updates
Table 105. Oncolytics Biotech Inc. Corporation Information
Table 106. Oncolytics Biotech Inc. Description and Business Overview
Table 107. Oncolytics Biotech Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 108. Oncolytics Biotech Inc. Metastatic Melanoma Drug Product
Table 109. Oncolytics Biotech Inc. Recent Developments/Updates
Table 110. OncoSec Medical Inc. Corporation Information
Table 111. OncoSec Medical Inc. Description and Business Overview
Table 112. OncoSec Medical Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 113. OncoSec Medical Inc. Metastatic Melanoma Drug Product
Table 114. OncoSec Medical Inc. Recent Developments/Updates
Table 115. Ono Pharmaceutical Co., Ltd. Corporation Information
Table 116. Ono Pharmaceutical Co., Ltd. Description and Business Overview
Table 117. Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 118. Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Product
Table 119. Ono Pharmaceutical Co., Ltd. Recent Developments/Updates
Table 120. Pfizer Inc. Corporation Information
Table 121. Pfizer Inc. Description and Business Overview
Table 122. Pfizer Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 123. Pfizer Inc. Metastatic Melanoma Drug Product
Table 124. Pfizer Inc. Recent Developments/Updates
Table 125. Pharmis Biofarmaceutica, Lda. Corporation Information
Table 126. Pharmis Biofarmaceutica, Lda. Description and Business Overview
Table 127. Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 128. Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Product
Table 129. Pharmis Biofarmaceutica, Lda. Recent Developments/Updates
Table 130. Philogen S.p.A. Corporation Information
Table 131. Philogen S.p.A. Description and Business Overview
Table 132. Philogen S.p.A. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 133. Philogen S.p.A. Metastatic Melanoma Drug Product
Table 134. Philogen S.p.A. Recent Developments/Updates
Table 135. Plexxikon Inc. Corporation Information
Table 136. Plexxikon Inc. Description and Business Overview
Table 137. Plexxikon Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 138. Plexxikon Inc. Metastatic Melanoma Drug Product
Table 139. Plexxikon Inc. Recent Developments/Updates
Table 140. Key Raw Materials Lists
Table 141. Raw Materials Key Suppliers Lists
Table 142. Metastatic Melanoma Drug Distributors List
Table 143. Metastatic Melanoma Drug Customers List
Table 144. Metastatic Melanoma Drug Market Trends
Table 145. Metastatic Melanoma Drug Market Drivers
Table 146. Metastatic Melanoma Drug Market Challenges
Table 147. Metastatic Melanoma Drug Market Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Metastatic Melanoma Drug
Figure 2. Global Metastatic Melanoma Drug Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Metastatic Melanoma Drug Market Share by Type in 2022 & 2034
Figure 4. AGI-134 Product Picture
Figure 5. ALT-801 Product Picture
Figure 6. ALT-803 Product Picture
Figure 7. AMG-232 Product Picture
Figure 8. Others Product Picture
Figure 9. Global Metastatic Melanoma Drug Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 10. Global Metastatic Melanoma Drug Market Share by Application in 2022 & 2034
Figure 11. Hospital
Figure 12. Clinic
Figure 13. Others
Figure 14. Global Metastatic Melanoma Drug Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 15. Global Metastatic Melanoma Drug Market Size (2018-2034) & (US$ Million)
Figure 16. Global Metastatic Melanoma Drug Sales (2018-2034) & (K Pcs)
Figure 17. Global Metastatic Melanoma Drug Average Price (USD/Pcs) & (2018-2034)
Figure 18. Metastatic Melanoma Drug Report Years Considered
Figure 19. Metastatic Melanoma Drug Sales Share by Manufacturers in 2022
Figure 20. Global Metastatic Melanoma Drug Revenue Share by Manufacturers in 2022
Figure 21. The Global 5 and 10 Largest Metastatic Melanoma Drug Players: Market Share by Revenue in 2022
Figure 22. Metastatic Melanoma Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 23. Global Metastatic Melanoma Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2034
Figure 24. North America Metastatic Melanoma Drug Sales Market Share by Country (2018-2034)
Figure 25. North America Metastatic Melanoma Drug Revenue Market Share by Country (2018-2034)
Figure 26. U.S. Metastatic Melanoma Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 27. Canada Metastatic Melanoma Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 28. Europe Metastatic Melanoma Drug Sales Market Share by Country (2018-2034)
Figure 29. Europe Metastatic Melanoma Drug Revenue Market Share by Country (2018-2034)
Figure 30. Germany Metastatic Melanoma Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 31. France Metastatic Melanoma Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 32. U.K. Metastatic Melanoma Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 33. Italy Metastatic Melanoma Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 34. Russia Metastatic Melanoma Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 35. Asia Pacific Metastatic Melanoma Drug Sales Market Share by Region (2018-2034)
Figure 36. Asia Pacific Metastatic Melanoma Drug Revenue Market Share by Region (2018-2034)
Figure 37. China Metastatic Melanoma Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 38. Japan Metastatic Melanoma Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 39. South Korea Metastatic Melanoma Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 40. India Metastatic Melanoma Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 41. Australia Metastatic Melanoma Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 42. Taiwan Metastatic Melanoma Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 43. Indonesia Metastatic Melanoma Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 44. Thailand Metastatic Melanoma Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 45. Malaysia Metastatic Melanoma Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 46. Philippines Metastatic Melanoma Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 47. Latin America Metastatic Melanoma Drug Sales Market Share by Country (2018-2034)
Figure 48. Latin America Metastatic Melanoma Drug Revenue Market Share by Country (2018-2034)
Figure 49. Mexico Metastatic Melanoma Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 50. Brazil Metastatic Melanoma Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 51. Argentina Metastatic Melanoma Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 52. Middle East & Africa Metastatic Melanoma Drug Sales Market Share by Country (2018-2034)
Figure 53. Middle East & Africa Metastatic Melanoma Drug Revenue Market Share by Country (2018-2034)
Figure 54. Turkey Metastatic Melanoma Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 55. Saudi Arabia Metastatic Melanoma Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 56. U.A.E Metastatic Melanoma Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 57. Global Sales Market Share of Metastatic Melanoma Drug by Type (2018-2034)
Figure 58. Global Revenue Market Share of Metastatic Melanoma Drug by Type (2018-2034)
Figure 59. Global Metastatic Melanoma Drug Price (USD/Pcs) by Type (2018-2034)
Figure 60. Global Sales Market Share of Metastatic Melanoma Drug by Application (2018-2034)
Figure 61. Global Revenue Market Share of Metastatic Melanoma Drug by Application (2018-2034)
Figure 62. Global Metastatic Melanoma Drug Price (USD/Pcs) by Application (2018-2034)
Figure 63. Metastatic Melanoma Drug Value Chain
Figure 64. Metastatic Melanoma Drug Production Process
Figure 65. Channels of Distribution (Direct Vs Distribution)
Figure 66. Distributors Profiles
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed